Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
John B. Mumm | M | - |
Deka Biosciences, Inc.
Deka Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Deka Biosciences, Inc. is a biotech company based in Germantown, MD. Deka Biosciences is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases. The company has developed disease-specific diakines™ that are designed to maximize patient benefits through improved pharmacokinetics/pharmacodynamics function by the targeted accumulation of dual and complimentary cytokines into affected tissues. Deka Biosciences aims to build specific targeted therapies for everyone by developing a better understanding of each patient's immune response to different diakines™. The company was founded in 2019 by John B. Mumm and Pavel Khrimian, with John B. Mumm serving as the CEO since then. | 5 años |
Peter Buzy | M | 64 |
Deka Biosciences, Inc.
Deka Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Deka Biosciences, Inc. is a biotech company based in Germantown, MD. Deka Biosciences is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases. The company has developed disease-specific diakines™ that are designed to maximize patient benefits through improved pharmacokinetics/pharmacodynamics function by the targeted accumulation of dual and complimentary cytokines into affected tissues. Deka Biosciences aims to build specific targeted therapies for everyone by developing a better understanding of each patient's immune response to different diakines™. The company was founded in 2019 by John B. Mumm and Pavel Khrimian, with John B. Mumm serving as the CEO since then. | - |
John Conner | M | - |
Deka Biosciences, Inc.
Deka Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Deka Biosciences, Inc. is a biotech company based in Germantown, MD. Deka Biosciences is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases. The company has developed disease-specific diakines™ that are designed to maximize patient benefits through improved pharmacokinetics/pharmacodynamics function by the targeted accumulation of dual and complimentary cytokines into affected tissues. Deka Biosciences aims to build specific targeted therapies for everyone by developing a better understanding of each patient's immune response to different diakines™. The company was founded in 2019 by John B. Mumm and Pavel Khrimian, with John B. Mumm serving as the CEO since then. | - |
Gráfico relacional
Relaciones con varias empresas
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 3 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Pavel Khrimian
- Red Personal